Form 4: Zoetis Executive Vice President Jeannette Ferran Astorga Reports Changes in Beneficial Ownership

Executive Vice President Jeannette Ferran Astorga reports changes in beneficial ownership of Zoetis Inc. securities, including the acquisition of phantom stock units and disposal of common stock.

Summary

• On July 12, 2024, Jeannette Ferran Astorga, an Executive Vice President at Zoetis Inc., reported changes in her beneficial ownership of the company's securities.
• She acquired 85.2401 phantom stock units pursuant to the Zoetis Supplemental Savings Plan.
• Additionally, she disposed of 27.3898 shares of common stock at a price of $57.53.
• Following these transactions, she beneficially owns 1,121.2554 derivative securities.
• The phantom stock units are settled in cash upon separation from service and can be transferred into an alternative investment fund.
• Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock plus a small amount of cash-equivalent investments.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating standard executive compensation practices. The disposal of a small number of shares is not necessarily indicative of negative sentiment.

Positives

• The acquisition of phantom stock units through the Zoetis Supplemental Savings Plan indicates a continued investment in the company's future by the executive.

Negatives

• The disposal of 27.3898 shares of common stock, while potentially for personal financial management, could be interpreted negatively by some investors if viewed in isolation.

Risks

• The document itself does not present any immediate risks.
• However, consistent patterns of stock disposal by executives could signal underlying concerns about the company's performance, warranting further investigation.

Future Outlook

The document does not contain explicit forward-looking statements, but the continued participation in the Zoetis Supplemental Savings Plan suggests a long-term commitment by the executive.

Industry Context

Form 4 filings are a routine part of executive compensation and ownership transparency in publicly traded companies like Zoetis. They provide insights into management's alignment with shareholder interests.

Comparison to Industry Standards

• Executive compensation packages often include phantom stock units as a way to align executive incentives with company performance, similar to practices at companies like Merck & Co. and Eli Lilly.
• The Zoetis Supplemental Savings Plan appears to be a standard deferred compensation plan, comparable to those offered by other large pharmaceutical and animal health companies.

Stakeholder Impact

• Shareholders may view the acquisition of phantom stock units positively as it aligns executive interests with company performance.
• The disposal of a small number of shares is unlikely to have a significant impact on stakeholders.

Key Dates